TOVALT ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOVALT ODT (TOVALT ODT).
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
| Metabolism | Metabolized primarily by CYP2B6 and CYP3A4 to N-desmethylselegiline, L-amphetamine, and L-methamphetamine. Other minor pathways include CYP2C19 and CYP2D6. |
| Excretion | Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal. |
| Half-life | Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks. |
| Protein binding | ~96% bound predominantly to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd ~1.5 L/kg, indicating extensive tissue distribution; large Vd suggests high lipophilicity. |
| Bioavailability | Sublingual: ~90% compared to oral due to avoidance of first-pass metabolism. |
| Onset of Action | Sublingual: detectable plasma levels within 10–15 minutes; peak clinical effect (anxiety relief) within 1–2 hours. |
| Duration of Action | Duration of anxiolytic effect ~7–8 hours after single dose; may persist longer with chronic dosing due to accumulation. |
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | For GFR 30-89 mL/min: no adjustment. For GFR <30 mL/min: initiate with 50% of usual dose and titrate cautiously due to increased fentanyl exposure. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: initiate with 50% of usual dose and titrate cautiously. Child-Pugh C: not recommended as metabolism is severely impaired. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate at 50% of usual adult dose (10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TOVALT ODT (TOVALT ODT).
| Breastfeeding | Topiramate is excreted into human milk; M/P ratio approximately 0.86. Infant plasma concentrations can reach therapeutic levels. Potential adverse effects include drowsiness, diarrhea, and poor weight gain. Breastfeeding is not recommended during maternal use of Tovalt ODT due to risk of infant toxicity. |
| Teratogenic Risk | Pregnancy Category X. Tovalt ODT (topiramate) is contraindicated in pregnancy due to increased risk of oral clefts (cleft lip/palate) and other congenital malformations (e.g., neural tube defects, hypospadias) when exposed during first trimester. Exposure in second/third trimester may be associated with decreased fetal growth, microcephaly, and neurodevelopmental impairments. Use effective contraception. |
■ FDA Black Box Warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors.
| Serious Effects |
Concomitant use with other MAOIs, pethidine (meperidine), tramadol, methadone, propoxyphene, St. John's wort, or other serotonergic drugs. Pheochromocytoma. Severe hepatic impairment. Elective surgery requiring general anesthesia.
| Precautions | Risk of hypertensive crisis with tyramine-rich foods or concomitant use of other MAOIs, serotonergic drugs, or sympathomimetics. May cause serotonin syndrome, exacerbation of Parkinson's disease, orthostatic hypotension, and impulse control disorders. Do not exceed recommended dose due to loss of MAO-B selectivity. |
Loading safety data…
| Fetal Monitoring | Monitor serum topiramate levels (therapeutic range 5-20 mcg/mL) every 1-3 months and adjust dose to maintain trough levels. Assess fetal growth via ultrasound every 4-6 weeks. Perform detailed fetal anatomy ultrasound at 18-22 weeks gestation. Monitor for signs of preeclampsia, gestational diabetes, and fetal distress. Postnatal surveillance for developmental milestones. |
| Fertility Effects | Topiramate may impair fertility in females by causing menstrual cycle irregularities and anovulation, possibly due to weight loss or hormonal effects. In males, no established effects on spermatogenesis or fertility, but data limited. Advise women of childbearing potential to use reliable contraception. |